<DOC>
	<DOCNO>NCT00049114</DOCNO>
	<brief_summary>Drugs use chemotherapy , doxorubicin cyclophosphamide , work different way stop tumor cell divide stop grow die . Tipifarnib may stop growth tumor cell block enzymes necessary growth . Combining tipifarnib doxorubicin cyclophosphamide may kill tumor cell . Phase II trial study effectiveness combine tipifarnib doxorubicin cyclophosphamide treat woman locally advance breast cancer .</brief_summary>
	<brief_title>Tipifarnib , Doxorubicin , Cyclophosphamide Treating Women With Locally Advanced Breast Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose tipifarnib administer doxorubicin cyclophosphamide woman metastatic breast cancer ( non-regional stage IV disease ) . ( Phase I close accrual 1/19/04 ) II . Determine pathologic complete remission rate patient locally advance breast cancer ( stage IIB , IIIA , IIIB , IIIC ) treat recommended phase II dose regimen . SECONDARY OBJECTIVES : I . Determine clinical complete response rate patient treat regimen . II . Determine toxicity profile regimen patient . III . Correlate pretreatment level ErbB1 , 2 , 3 , 4 phosphorylated level Akt , STAT3 , Erk ½ clinical response patient percent inhibition proliferation ( Ki-67 ) percent induction apoptosis post-treatment tumor specimen . IV . Correlate percent decrease farnesyltransferase ( FTase ) activity level , HDJ-2 farnesylation , phospho-Akt , phospho-STAT3 , phospho-Erk ½ clinical response rate patient percent inhibition proliferation ( Ki-67 ) percent inhibition apoptosis . OUTLINE : This multicenter , dose-escalation study tipifarnib . Patients stratify accord presence inflammatory carcinoma ( yes v ) . PHASE I ( nonregional stage IV disease ) ( close accrual 1/19/04 ) : Patients receive doxorubicin IV 10-15 minute cyclophosphamide IV 30 minute day 1 , oral tipifarnib twice daily day 2-7 , filgrastim ( G-CSF ) subcutaneously day 2-13 . Treatment repeat every 2 week 4 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos tipifarnib maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . PHASE II ( stage IIB , IIIA , IIIB , IIIC ) : Patients receive tipifarnib MTD doxorubicin , cyclophosphamide , G-CSF phase I ( phase I close accrual 1/19/04 ) . After fourth course , patient may undergo complete resection . Patients follow every 3-4 month 3 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : Approximately 3-12 patient accrued phase I ( close accrual 1/19/04 ) study . A total 21-50 patient accrue phase II study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Inflammatory Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Tipifarnib</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma breast Phase I ( close accrual 1/19/04 ) : Nonregional stage IV disease Phase II : Locally advanced disease , accord AJCC stag criterion : Stage IIB Stage IIIA Stage IIIB Stage IIIC At least 1 bidimensionally unidimensionally measurable indicator lesion Hormone receptor status : Not specify Female Performance status ECOG 01 Performance status Karnofsky 70100 % Not specify WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Bilirubin normal AST/ALT great 2.5 time upper limit normal Creatinine normal Creatinine clearance least 60 mL/min LVEF normal No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia No invasive malignancy within past 5 year except curatively treat basal cell squamous cell skin cancer carcinoma situ cervix No prior allergic reaction attribute compound similar chemical biological composition tipifarnib agent use study ( e.g. , imidazoles quinolones ) No ongoing active infection No concurrent uncontrolled illness would preclude study participation No psychiatric illness social situation would preclude study compliance Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Not specified Phase I ( close accrual 1/19/04 ) : More 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover No 1 prior adjuvant/neoadjuvant regimen 1 prior regimen metastatic disease Prior doxorubicin allow provided follow true : Used adjuvant set Cumulative dose great 240 mg/m^2 At least 1 year completion adjuvant therapy relapse Phase II : No prior chemotherapy locally advance breast cancer At least 1 week since prior tamoxifen selective estrogen receptor modulators prevention indication ( e.g. , osteoporosis , ductal carcinoma situ , invasive breast cancer ) Phase I ( close accrual 1/19/04 ) : More 4 week since prior radiotherapy Phase II : No prior radiotherapy locally advance breast cancer Not specify No antacid within 2 hour study drug administration No concurrent combination antiretroviral therapy HIVpositive patient No concurrent anticancer therapy No concurrent investigational agent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>